Drug transporters in drug efficacy and toxicity.
暂无分享,去创建一个
P. Sexton | R. Kim | R. Lefkowitz | A. Gilman | J. Idle | F. Gonzalez | M. DeGorter | C. Xia | J. Yang | A. Patterson | Atwood K Cheung | Shih-Min A. Huang | M.K. DeGorter | C.Q. Xia | J.J. Yang | R.B. Kim | Toshio Tanaka | J. Yang
[1] K. Giacomini,et al. Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin Pharmacokinetics , 2008, Clinical pharmacology and therapeutics.
[2] Stephen G. Aller. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2010 .
[3] Hyunyoung Jeong,et al. Induction of CYP2B6 and CYP3A4 expression by 1-aminobenzotriazole (ABT) in human hepatocytes. , 2010, Drug metabolism letters.
[4] H. Potschka. Modulating P‐glycoprotein regulation: Future perspectives for pharmacoresistant epilepsies? , 2010, Epilepsia.
[5] R. Kaiser,et al. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron , 2010, The Pharmacogenomics Journal.
[6] P. Neuvonen,et al. Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. , 2011, British journal of clinical pharmacology.
[7] Yuichi Sugiyama,et al. Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans , 2008, Clinical pharmacology and therapeutics.
[8] B. Tomlinson,et al. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients , 2010, Pharmacogenetics and genomics.
[9] A. Schinkel,et al. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. , 2009, Advanced drug delivery reviews.
[10] A. Hofman,et al. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus , 2009, The Pharmacogenomics Journal.
[11] Caroline A. Lee,et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment , 2005, Clinical pharmacology and therapeutics.
[12] Matthijs L. Becker,et al. Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study , 2009, Diabetes.
[13] A. S. Gross,et al. Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. , 2010, Journal of pharmaceutical sciences.
[14] M. Namer,et al. CLINICAL AND PHARMACOKINETIC EVIDENCE OF A LIFE-THREATENING INTERACTION BETWEEN METHOTREXATE AND KETOPROFEN , 1986, The Lancet.
[15] D. Keppler,et al. The apical conjugate efflux pump ABCC2 (MRP2) , 2007, Pflügers Archiv - European Journal of Physiology.
[16] S. Tsunoda,et al. ABCG2 Expression Is an Independent Unfavorable Prognostic Factor in Esophageal Squamous Cell Carcinoma , 2007, Oncology.
[17] Samy I McFarlane,et al. Metformin: An Update , 2002, Annals of Internal Medicine.
[18] H. Takane,et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin , 2006, Journal of Human Genetics.
[19] B. Tomlinson,et al. ABCG2 Polymorphism Is Associated With the Low‐Density Lipoprotein Cholesterol Response to Rosuvastatin , 2010, Clinical pharmacology and therapeutics.
[20] P. Kwok,et al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1 , 2009, Pharmacogenetics and genomics.
[21] E. van de Steeg,et al. High Impact of Oatp1a/1b Transporters on In Vivo Disposition of the Hydrophobic Anticancer Drug Paclitaxel , 2010, Clinical Cancer Research.
[22] Andreas Rolfs,et al. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins , 2004, Pflügers Archiv.
[23] N. Samani,et al. Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction: The GEOSTAT-1 Study , 2010, Circulation. Cardiovascular genetics.
[24] E. Burchard,et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin , 2009, Pharmacogenetics and genomics.
[25] H. Koepsell,et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. , 2010, The American journal of pathology.
[26] G. Burckhardt,et al. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. , 2011, Handbook of experimental pharmacology.
[27] H. McLeod,et al. Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics , 2007, Clinical pharmacology and therapeutics.
[28] H. Kusuhara,et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. , 2004, Drug metabolism and pharmacokinetics.
[29] A. Fujimura,et al. Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: First case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2 , 2006, Clinical pharmacology and therapeutics.
[30] S. Bates,et al. ABCG2: a perspective. , 2009, Advanced drug delivery reviews.
[31] R. Franke,et al. Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl-β-D-Glucosaminidase , 2010, Clinical Cancer Research.
[32] K. Maeda,et al. Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.
[33] M. McCarthy,et al. Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study , 2009, Diabetes.
[34] R. Callaghan,et al. How can we best use structural information on P-glycoprotein to design inhibitors? , 2007, Pharmacology & therapeutics.
[35] H. Koepsell,et al. Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications , 2007, Pharmaceutical Research.
[36] R. Kim,et al. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. , 2010, American journal of physiology. Renal physiology.
[37] O. van Tellingen,et al. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo , 2009, Molecular Cancer Therapeutics.
[38] J. Schellens,et al. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib , 2009, Investigational New Drugs.
[39] Yuichi Sugiyama,et al. Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin , 2002, Journal of Pharmacology and Experimental Therapeutics.
[40] T. Miyawaki,et al. Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. , 2011, Drug metabolism and pharmacokinetics.
[41] H. Kusuhara,et al. Prediction of Fluoroquinolone‐Induced Elevation in Serum Creatinine Levels: A Case of Drug–Endogenous Substance Interaction Involving the Inhibition of Renal Secretion , 2011, Clinical pharmacology and therapeutics.
[42] T. Dale,et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk , 2005, Nature Medicine.
[43] C. Beglinger,et al. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. , 2005, Biochemical pharmacology.
[44] T. Ishikawa,et al. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. , 2009, Journal of experimental therapeutics & oncology.
[45] O. Ogawa,et al. Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney , 2008, Journal of Human Genetics.
[46] Swati S. More,et al. Role of Organic Cation Transporter 1, OCT1 in the Pharmacokinetics and Toxicity of cis-Diammine(pyridine)chloroplatinum(II) and Oxaliplatin in Mice , 2010, Pharmaceutical Research.
[47] M. Gionfriddo,et al. Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. , 2009, Biopharmaceutics & drug disposition.
[48] H. Endou,et al. Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms. , 2010, Journal of pharmacological sciences.
[49] A. Wolff,et al. Pharmacogenetic Pathway Analysis of Docetaxel Elimination , 2009, Clinical pharmacology and therapeutics.
[50] Rachel M. Bailey,et al. Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G. , 2007, American journal of physiology. Renal physiology.
[51] Joseph W. Polli,et al. An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) , 2009, Drug Metabolism and Disposition.
[52] I. Roots,et al. Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin’s cholesterol lowering capabilities and basal sterol serum levels , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.
[53] P. Neuvonen,et al. Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.
[54] T. Mizuno,et al. Targeted Disruption of the Multidrug and Toxin Extrusion 1 (Mate1) Gene in Mice Reduces Renal Secretion of Metformin , 2009, Molecular Pharmacology.
[55] D. Keppler,et al. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). , 2004, Pharmacogenetics.
[56] L. Doyle,et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[57] Shuzhong Zhang,et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. , 2006, Cancer research.
[58] D. Oh,et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers , 2005, Clinical pharmacology and therapeutics.
[59] TP Hughes,et al. OCT‐1 as a Determinant of Response to Antileukemic Treatment , 2011, Clinical pharmacology and therapeutics.
[60] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[61] K. Park,et al. Rifampin Enhances the Glucose‐Lowering Effect of Metformin and Increases OCT1 mRNA Levels in Healthy Participants , 2011, Clinical pharmacology and therapeutics.
[62] H. Koepsell,et al. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. , 2011, Handbook of experimental pharmacology.
[63] Liang-Shang Gan,et al. Breast cancer resistance protein in pharmacokinetics and drug–drug interactions , 2005, Expert opinion on drug metabolism & toxicology.
[64] U. Hofmann,et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid‐lowering efficacy of multiple‐dose pravastatin , 2006, Clinical pharmacology and therapeutics.
[65] U. Pagotto,et al. Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. , 2010, The Journal of clinical endocrinology and metabolism.
[66] Mikko Niemi,et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.
[67] D. Steinbach,et al. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia , 2002, Leukemia.
[68] A. Schinkel,et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.
[69] P. Kwok,et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function , 2009, The Pharmacogenomics Journal.
[70] H. Endou,et al. Characterization of Methotrexate Transport and Its Drug Interactions with Human Organic Anion Transporters , 2002, Journal of Pharmacology and Experimental Therapeutics.
[71] R. Kim,et al. Polymorphisms in OATP-C , 2001, The Journal of Biological Chemistry.
[72] A. Sparreboom,et al. Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin‐Induced Nephrotoxicity , 2009, Clinical pharmacology and therapeutics.
[73] G. Ginsburg,et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.
[74] P. Neuvonen,et al. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin , 2006, Clinical pharmacology and therapeutics.
[75] H. Kusuhara,et al. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. , 2003, Molecular pharmacology.
[76] R. Kim,et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants , 2007, Pharmacogenetics and genomics.
[77] J. Lima,et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response , 2009, Pharmacogenetics and genomics.
[78] T. Litman,et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.
[79] Jae-Gook Shin,et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15 , 2008, Pharmacogenetics and genomics.
[80] Mikko Niemi,et al. Role of OATP transporters in the disposition of drugs. , 2007, Pharmacogenomics.
[81] M. Washington,et al. Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. , 2008, Cancer research.
[82] Joe Palandra,et al. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe , 2008, Pharmacogenetics and genomics.
[83] P. Neuvonen,et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.
[84] A. Yonezawa,et al. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. , 2010, Biochemical pharmacology.
[85] I Meineke,et al. The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin , 2009, Clinical pharmacology and therapeutics.
[86] Jos H Beijnen,et al. Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration , 2012, International journal of cancer.
[87] J. Ware,et al. Breast Cancer Resistance Protein (BCRP/ABCG2) is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse , 2006, Molecular pharmaceutics.
[88] K. Inui,et al. Reduced Renal Clearance of a Zwitterionic Substrate Cephalexin in Mate1-Deficient Mice , 2010, Journal of Pharmacology and Experimental Therapeutics.
[89] H. Kusuhara,et al. Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Res , 2009, Drug Metabolism and Disposition.
[90] O. Ogawa,et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. , 2006, Journal of the American Society of Nephrology : JASN.
[91] Conrad C. Huang,et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. , 2002, Pharmacogenetics.
[92] A. Sparreboom,et al. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel , 2005, Cancer biology & therapy.
[93] A. V. van Herwaarden,et al. The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin , 2005, Molecular Pharmacology.
[94] Munir Pirmohamed,et al. Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.
[95] I. Song,et al. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. , 2008, Drug metabolism and pharmacokinetics.
[96] B. Stieger,et al. Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil , 2007, Drug Metabolism and Disposition.
[97] Ya-li Liu,et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[98] Cheng Cheng,et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] Vincenzo,et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.
[100] Xingrong Liu,et al. Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. , 2003, Current drug metabolism.
[101] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[102] H. Rosing,et al. P-Glycoprotein (ABCB1) Transports the Primary Active Tamoxifen Metabolites Endoxifen and 4-Hydroxytamoxifen and Restricts Their Brain Penetration , 2011, Journal of Pharmacology and Experimental Therapeutics.
[103] S. Cole,et al. Involvement of NHERF1 in apical membrane localization of MRP4 in polarized kidney cells. , 2009, Biochemical and biophysical research communications.
[104] D. Ross,et al. Impact of breast cancer resistance protein on cancer treatment outcomes. , 2010, Methods in molecular biology.
[105] S. Khoo,et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms , 2010, Pharmacogenetics and genomics.
[106] Soma Das,et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] J. Shin,et al. Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin , 2008, Clinical pharmacology and therapeutics.
[108] Ting-ting Li,et al. Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers , 2011, European Journal of Clinical Pharmacology.
[109] J. Lima,et al. Effect of Citrus Juice and SLCO2B1 Genotype on the Pharmacokinetics of Montelukast , 2011, Journal of clinical pharmacology.
[110] T. Cihlar,et al. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. , 2000, The Journal of pharmacology and experimental therapeutics.
[111] S. Cole,et al. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. , 2006, Physiological reviews.
[112] K. Maeda,et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril , 2006, Clinical pharmacology and therapeutics.
[113] T. Doi,et al. Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity , 2009, Journal of Human Genetics.
[114] O. Legrand,et al. Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias , 2004, Clinical Cancer Research.
[115] Conrad C. Huang,et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[116] E. Schuetz,et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. , 2003, Pharmacogenetics.
[117] O. van Tellingen,et al. Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo , 2009, Clinical Cancer Research.
[118] H. Glaeser. Importance of P-glycoprotein for drug-drug interactions. , 2011, Handbook of experimental pharmacology.
[119] Yi Wang,et al. Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.
[120] Supratim Choudhuri,et al. Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[121] H. Koepsell,et al. Organic cation transporters in intestine, kidney, liver, and brain. , 1998, Annual review of physiology.
[122] K. Mizuguchi,et al. Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity , 2011, Pharmacogenetics and genomics.
[123] E. Lopez-Lopez,et al. Polymorphisms of the SLCO1B1 gene predict methotrexate‐related toxicity in childhood acute lymphoblastic leukemia , 2011, Pediatric blood & cancer.
[124] H. Kusuhara,et al. P-GLYCOPROTEIN PLAYS A MAJOR ROLE IN THE EFFLUX OF FEXOFENADINE IN THE SMALL INTESTINE AND BLOOD-BRAIN BARRIER, BUT ONLY A LIMITED ROLE IN ITS BILIARY EXCRETION , 2005, Drug Metabolism and Disposition.
[125] V. Vallon,et al. Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. , 2008, American journal of physiology. Renal physiology.
[126] F. Sharom. ABC multidrug transporters: structure, function and role in chemoresistance. , 2008, Pharmacogenomics.
[127] Rosalinde Masereeuw,et al. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. , 2008, Trends in pharmacological sciences.
[128] Bradley L Urquhart,et al. Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins , 2010, Circulation research.
[129] Shuzhong Zhang,et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.
[130] U. Brinkmann,et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. , 2002, Pharmacogenetics.
[131] M. Relling,et al. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. , 2008, Cancer Research.
[132] 坂田 武. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions , 2004 .
[133] P. Manley,et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[134] Mikko Niemi,et al. Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.
[135] T. Lumley,et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis , 2011, Pharmacogenetics and genomics.
[136] K. Maeda,et al. SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.
[137] K. Giacomini,et al. Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions , 2011, The Pharmacogenomics Journal.
[138] Hyeong-Seok Lim,et al. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. , 2008, Lung cancer.
[139] M. Niemi,et al. Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.
[140] I. Cascorbi. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. , 2011, Handbook of experimental pharmacology.
[141] A. Schlessinger,et al. Genetic Polymorphisms in Organic Cation Transporter 1 (OCT1) in Chinese and Japanese Populations Exhibit Altered Function , 2010, Journal of Pharmacology and Experimental Therapeutics.
[142] S. Masuda,et al. Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. , 2010, Pharmacogenetics and genomics.
[143] R. Kim,et al. Organic Anion–Transporting Polypeptides , 2006 .
[144] P. Neuvonen,et al. Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide , 2008, Journal of clinical pharmacology.
[145] H. Kroemer,et al. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). , 2011, Handbook of experimental pharmacology.
[146] R. Kim,et al. Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1) , 2011, Drug Metabolism and Disposition.
[147] Mark N Milton,et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. , 2010, Drug metabolism letters.
[148] S. Masuda,et al. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. , 2009, Biochemical pharmacology.
[149] M. F. Kanz,et al. Intestinal tract injury by drugs: Importance of metabolite delivery by yellow bile road. , 2006, Pharmacology & therapeutics.
[150] R. Kim,et al. Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). , 2008, Drug metabolism reviews.
[151] B. Stricker,et al. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response , 2010, Pharmacogenetics and genomics.
[152] M. Hayden,et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin , 2011, The Pharmacogenomics Journal.
[153] Balram Chowbay,et al. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients , 2006, Pharmacogenetics and genomics.
[154] Hiroaki Yuasa,et al. The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine , 2009, Drug Metabolism and Disposition.
[155] B. Långström,et al. Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport , 2009, Drug Metabolism and Disposition.
[156] Junjeong Choi,et al. Influence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans , 2008, Clinical pharmacology and therapeutics.
[157] H. Rosing,et al. Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B2) into Milk , 2006, Molecular and Cellular Biology.
[158] Yibo Wang,et al. Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide. , 2011, American journal of hypertension.
[159] Yuichi Sugiyama,et al. Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.
[160] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[161] Wolfgang Löscher,et al. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases , 2005, Progress in Neurobiology.
[162] K. Giacomini,et al. Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins , 2011, Molecular Cancer Therapeutics.
[163] P. Neuvonen,et al. Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.
[164] A. Morris,et al. Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go‐DARTS Study , 2011, Clinical pharmacology and therapeutics.
[165] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[166] M. Krajinovic,et al. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. , 2009, Blood.
[167] Yusuke Nakamura,et al. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia , 2008, Cancer science.
[168] Adam L VanWert,et al. Organic Anion Transporter 3 (Oat3/Slc22a8) Interacts with Carboxyfluoroquinolones, and Deletion Increases Systemic Exposure to Ciprofloxacin , 2008, Molecular Pharmacology.
[169] R. Kim,et al. Transporters and drug therapy: Implications for drug disposition and disease , 2005, Clinical pharmacology and therapeutics.
[170] M. Gottesman,et al. Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.
[171] C. Rudin,et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[172] Teruhiko Yoshida,et al. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients , 2010, Cancer Chemotherapy and Pharmacology.
[173] U. Hofmann,et al. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). , 2005, British journal of clinical pharmacology.
[174] P. Giral,et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. , 2008, Pharmacogenomics.
[175] U. Hofmann,et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17 , 2005, Pharmacogenetics and genomics.
[176] Jos H. Beijnen,et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein , 1997, Nature Medicine.
[177] D. Keppler,et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver , 2009, Hepatology.
[178] S. Cole,et al. Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1) , 2005, Pharmacogenetics and genomics.
[179] José Manuel Fernández-Real,et al. OCT1 Expression in Adipocytes Could Contribute to Increased Metformin Action in Obese Subjects , 2010, Diabetes.
[180] Brian Tomlinson,et al. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine , 2008, Pharmacogenetics and genomics.
[181] P. Neuvonen,et al. ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.
[182] Steffen Bauer,et al. Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.
[183] R. Kim,et al. Targeted Disruption of Murine Organic Anion-Transporting Polypeptide 1b2 (oatp1b2/Slco1b2) Significantly Alters Disposition of Prototypical Drug Substrates Pravastatin and Rifampin , 2008, Molecular Pharmacology.
[184] E. van de Steeg,et al. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. , 2010, The Journal of clinical investigation.
[185] J. Schellens,et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.
[186] S. D. de Morais,et al. Utility of a Novel Oatp1b2 Knockout Mouse Model for Evaluating the Role of Oatp1b2 in the Hepatic Uptake of Model Compounds , 2008, Drug Metabolism and Disposition.
[187] G. Suarez-Kurtz,et al. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. , 2010, British journal of clinical pharmacology.
[188] P. Neuvonen,et al. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. , 2009, Pharmacogenomics.
[189] M. Niemi,et al. Grapefruit Juice Greatly Reduces the Plasma Concentrations of the OATP2B1 and CYP3A4 Substrate Aliskiren , 2010, Clinical pharmacology and therapeutics.
[190] Hiroshi Omote,et al. A human transporter protein that mediates the final excretion step for toxic organic cations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[191] M. Kool,et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin‐Johnson syndrome , 1997, Hepatology.
[192] H. Trautmann,et al. Multidrug resistance-associated protein 4 (MRP4) gene polymorphisms and treatment response in adult acute lymphoblastic leukemia. , 2009, Blood.
[193] L. Chinn,et al. ABCB1 Pharmacogenetics: Progress, Pitfalls, and Promise , 2007, Clinical pharmacology and therapeutics.